Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.

Research into Cold Cancers Heating Up

Activation and expansion are essential for success in both autologous and allogeneic therapies.

Development of Gamma-Delta T-Cell Therapies

Continuous manufacturing and a quality-by-design development approach are a natural fit.

QbD for Small-Molecule Continuous Process Development

Topic

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Articles

Warp speed is amazoning pharma practices and protocols.

Industrious Pharmaceuticals

Christa Myers is a process chemical engineer for CRB.

A new focus on speed to market creates challenges for facility design and construction.

The Need for Speed: How Operation Warp Speed Shifted the Pharma Industry

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Dosage form and patient needs drive excipient choice.

Taste and Appearance: Selecting the Right Excipients 

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Poor solubility remains a big issue for drug development and, as such, is driving innovation in approaches and use of novel technologies to help overcome the associated challenges.

Tackling the Big Issue of Solubility

Feliza Mirasol is the science editor for 

There is need for training personnel in various analytical skill sets for biologic drug substance testing.

Biologics Testing Highlights Need for Analytical Skills

Cheryl Barton is director of PharmaVision, 

DTx manufacturers are taking advantage of the new regulatory flexibility, afforded by the COVID-19 pandemic, to pilot new products and generate real-world evidence to support regulatory filing and reimbursement.

Regulating Digital Therapeutics

Amgen and Syngene International have extended their research collaboration to 2026.

Amgen Extends Collaboration with Syngene International

GlaxoSmithKline, together with the University of Oxford, has launched the Oxford-GSK Institute under a new collaboration that aims to study complex diseases to accelerate the success of drug discovery and drug development efforts.

GSK and University of Oxford Partner on Disease Research to Advance Drug Discovery and Development

Lonza has signed a five-year services agreement to provide for the development and manufacturing of biologics and small molecules for portfolio companies owned by Bioqube Ventures.

Lonza and Bioqube Ventures Form Agreement for Future Development and Manufacture of Biologics and Small Molecules

Sanofi’s acquisition of Origimm Biotechnology will add to its pipeline of vaccine candidates for treating acne.

Drug Development

Research into Cold Cancers Heating Up

Development of Gamma-Delta T-Cell Therapies

QbD for Small-Molecule Continuous Process Development